Melanomas are the tumour pathologies in which GWL mutations have been most frequently detected (18%) followed by esophageal cancer (15%) and ovarian cancer (9%), however again, most GWL mutations detected in these cancers concern non-coding mutations or mutations at the T-loop fragment. This evidence concerns the gene MASTL and ovarian cancer.